Cranbury, New Jersey – Palatin Technologies, Inc. held their Q4 2024 Earnings Conference Call on October 1, 2024, at 11:00 AM ET. The call included key Company Participants, such as Carl Spana, the Chief Executive Officer and President, and Stephen Wills, who serves as the Chief Financial Officer, Chief Operating Officer, Treasurer, and Secretary.

During the conference call, various industry experts like Joe Pantginis from H.C. Wainwright and John Newman from Canaccord Genuity participated, engaging in discussions covering Palatin’s fourth-quarter and fiscal year-end 2024 operating results. The call was conducted in a listen-only mode with a question-and-answer session following the formal presentation.

Before delving into the financial updates, it was emphasized that statements made by Palatin are forward-looking and not historical facts. The discussions were based on assumptions that may influence actual results, highlighting the risks and uncertainties mentioned in the company’s recent filings with the Securities and Exchange Commission.

Dr. Carl Spana, Palatin’s President and Chief Executive Officer, began by welcoming participants to the year-end fiscal 2024 call and introduced Steve Wills, the company’s Chief Financial Officer and Chief Operating Officer. Steve proceeded to provide insights into the financial results and highlighted corporate developments, specifically focusing on Vyleesi, a commercial product designed for hypoactive sexual desire disorder (HSDD).

Overall, the conference call served as a platform to discuss Palatin’s achievements and challenges, setting the tone for the company’s future endeavors in the pharmaceutical industry. The partnership between Carl Spana and Steve Wills showcased a dynamic leadership approach, addressing critical financial and operational aspects to drive growth and innovation in the market.